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Amyotrophic Lateral Sclerosis (ALS) is a fatal motoneuron disease that is characterized by the degradation of neurons throughout
the central nervous system. Inflammation have been cited a key contributor to ALS neurodegeneration, but the timeline of
cytokine upregulation remains unresolved. The goal of this study was to temporally examine the correlation between the varying
levels of pro‐inflammatory type I cytokines (IL‐1β, IL‐1α, IL‐12, TNF‐α, and GFAP) and anti‐inflammatory type II cytokines (IL‐4, IL‐6,
IL-10) throughout the progression of ALS in the SOD1 G93A mouse model. Cytokine level data from high copy SOD1 G93A transgenic
mice was collected from 66 peer-reviewed studies. For each corresponding experimental time point, the ratio of transgenic to
wild type (TG/WT) cytokine was calculated. One-way ANOVA and t-tests with Bonferonni correction were used to analyze the data.
 Meta-analysis was performed for four discrete stages: early, pre-onset, post-onset, and end stage. A significant increase in TG
cytokine levels was found when compared to WT cytokine levels across the entire SOD1 G93A lifespan for majority of the cytokines.
The rates of change of the individual cytokines, and type I and type II were not significantly different; however, the mean fold
change of type I was expressed at significantly higher levels than type II levels across all stages with the difference between the
means becoming more pronounced at the end stage. An overexpression of cytokines occurred both before and after the onset of
ALS symptoms.  The trend between pro-inflammatory type I and type II cytokine mean levels indicate a progressive instability of
the dynamic balance between pro- and anti-inflammatory cytokines as anti-inflammatory cytokines fail to mediate the pronounced
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Amyotrophic Lateral Sclerosis (ALS) is a fatal motoneuron disease that is characterized by the 13 
degradation of neurons throughout the central nervous system. Inflammation have been cited a 14 
key contributor to ALS neurodegeneration, but the timeline of cytokine upregulation remains 15 
unresolved. The goal of this study was to temporally examine the correlation between the 16 
varying levels of pro-inflammatory type I cytokines (IL-1β, IL-1α, IL-12, TNF-α, and GFAP) 17 
and anti-inflammatory type II cytokines (IL-4, IL-6, IL-10) throughout the progression of ALS in 18 
the SOD1 G93A mouse model. Cytokine level data from high copy SOD1 G93A transgenic mice 19 
was collected from 66 peer-reviewed studies. For each corresponding experimental time point, 20 
the ratio of transgenic to wild type (TG/WT) cytokine was calculated. One-way ANOVA and t-21 
tests with Bonferonni correction were used to analyze the data.  Meta-analysis was performed for 22 
four discrete stages: early, pre-onset, post-onset, and end stage. A significant increase in TG 23 
cytokine levels was found when compared to WT cytokine levels across the entire SOD1 G93A 24 
lifespan for majority of the cytokines. The rates of change of the individual cytokines, and type I 25 
and type II were not significantly different; however, the mean fold change of type I was 26 
expressed at significantly higher levels than type II levels across all stages with the difference 27 
between the means becoming more pronounced at the end stage. An overexpression of cytokines 28 
occurred both before and after the onset of ALS symptoms.  The trend between pro-29 
inflammatory type I and type II cytokine mean levels indicate a progressive instability of the 30 
dynamic balance between pro- and anti-inflammatory cytokines as anti-inflammatory cytokines 31 
fail to mediate the pronounced increase in pro-inflammatory cytokines.  Very early 32 
immunoregulatory treatment is necessary to successfully interrupt ALS-induced 33 
neuroinflammation.  34 
 35 




  40 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease that is characterized by 41 
the rapid degradation of motor neurons over the course of the disease, resulting in paralysis, 42 
respiratory failure, and ultimately death.  ALS is multi-faceted pathophysiology, which includes 43 
axonal transport, apoptosis, cellular chemistry, cellular energetics, inflammation, oxidative 44 
stress, proteomics, and systemic contributors.  Inflammation, or more specifically 45 




which is frequently assessed in the familial or transgenic superoxide dismutase-1 guanine 93 to 47 
alanine (SOD1 G93A) murine model (Pfohl et al., 2015a). Although the crucial role of 48 
neuroinflammation in the pathology of ALS is evident, the extent to which the inflammatory 49 
response is neurotoxic, and the balance of the inflammatory regulation and deregulation over the 50 
course of the disease progression remain unclear (McCombe and Henderson, 2011;Evans et al., 51 
2013). 52 
 53 
Currently, the drug Riluzole has shown to be slightly effective in extending patient survival by 54 
75 days through targeting inflammation caused by glutamate (Riviere et al., 1998;McGeer and 55 
McGeer, 2002). Other inflammatory treatments have also shown to significantly increase life 56 
expectancy. The inflammatory enzyme COX-2 has been found in high levels in G93A mice 57 
(Almer et al., 2001), and in vivo trials in mice using COX-2 inhibitors have yielded great results, 58 
extending life expectancy by upwards of 20% (Drachman et al., 2002). Possible treatments 59 
reducing pathological inflammation regulation may be used in conjunction to achieve a greater 60 
impact in the treatment of ALS (McGeer and McGeer, 2002). 61 
 62 
Cytokines, the primary messenger molecules of the inflammatory response, are released from 63 
leukocytes, microglia, and astrocytes (HART, 2003). In a non-pathological state, cytokines use 64 
complex signaling cascades in order to yield a balanced and non-toxic, protective immune 65 
response to the target site (Greenhalgh and Hilton, 2001).  Type I cytokines increase the 66 
inflammatory response (i.e. type I = pro-inflammatory), while type II cytokines decrease the 67 
inflammatory response (i.e. type II = anti-inflammatory) (Dong, 2011).   However, pathological 68 
overexpression of cytokines or disturbance of their intricate balance can cause the overall 69 
inflammatory response to be damaging rather than protective (Papadimitriou et al., 2010). 70 
Possible primary inducers of ALS inflammation include glutamate excitotoxicity and oxidative 71 
stress due to free radical accumulation (Mitchell and Lee, 2012;Kim et al., 2015). Primary and 72 
secondary activation of microglia and astrocytes further exacerbates the release of pro-73 
inflammatory cytokines and nitric oxide through a positive feedback loop (Mitchell and Lee, 74 
2008). 75 
 76 
Upregulation of pro-inflammatory cytokines is thought to be associated with an increased 77 
severity of symptoms in ALS (Nguyen et al., 2004).  However, the exact timeline of cytokine 78 
disturbance remains unclear (McCombe and Henderson, 2011).  In this study, we present a 79 
quantitative, comprehensive examination of cytokines over the entire course of the SOD1 G93A 80 
transgenic mouse ALS disease progression.  Moreover, we assess the relationship between type I 81 
and type II cytokines as a function of ALS progression. We hypothesized that type I cytokine 82 
levels would increase significantly in comparison to type II cytokine levels at each disease stage 83 
with this difference more pronounced in the latter stages of the disease. Our meta-analysis 84 
includes data from 66 peer-reviewed experimental studies, which measured cytokine levels in 85 
both transgenic G93A SOD1 mice (TG) and in wild type mice (WT). The fold changes, with 86 
respect to WT levels, of cytokines are compared across the lifespan of the SOD1 G93A TG 87 
mouse, using four discrete disease stages—early, pre-symptom onset, post-symptom onset, and 88 







Literature Search 93 
To obtain the initial primary article selection pool, PubMed searches were conducted in October 94 
2014 to find all published articles with (“Amyotrophic Lateral Sclerosis” OR “ALS”) in the title 95 
or abstract AND (“transgenic mouse” OR “G93A”) in the title or abstract (Kim et al., 2015;Pfohl 96 
et al., 2015b). Initial primary article selection pool exclusion criteria consisted of:  non-English 97 
language articles; articles for which full-text pdf downloads were unavailable; and articles 98 
labeled as literature reviews.  Articles were either downloaded using PubMed Central or from e-99 
journal subscriptions available from the libraries of Georgia Institute of Technology and Emory 100 
University.    101 
 102 
Information from the articles was entered systematically into a relational database using the 103 
software FileMaker Pro 13 Advanced (Filemaker, Inc.) (Kim et al., 2015) and included stringent 104 
quality control procedures (Mitchell et al., 2015a).  Aggregate data pertaining to cytokine levels of 105 
TG mice was mined using a predetermined list of cytokines (Table 1), which included alternate 106 
spellings (e.g. IL-1α, interleukin 1a, IL-1a, IL-alpha, IL-1(alpha), etc.).  Searches were 107 
performed in the article title, abstract, figure captions, and within figure text to find relevant 108 
articles from the primary article pool (Kim et al., 2015;Pfohl et al., 2015b). These searches 109 
resulted in a study selection pool of 153 articles from which initial data was collected.  The 110 
following list of inclusion and exclusion criteria was used to extract data relevant to cytokine 111 
levels from the study selection pool.  112 
 113 
Study Inclusion Criteria 114 
• Cytokines and small proteins that were directly related with cytokine effects.  Table 1 115 
provides a brief outline of the cytokines measured in this study (Ferguson-Smith et al., 116 
1988;Kriegler et al., 1988;Hsieh et al., 1993;Eskdale et al., 1997;Suzuki et al., 117 
2003;Ribotta et al., 2004;von Boyen et al., 2004;Sokol et al., 2008;Dinarello, 118 
2011;Pedersen, 2013). Although glial fibrillary acid protein (GFAP) is not a cytokine, it 119 
was categorized with type I cytokines, since GFAP levels correlates directly with an 120 
increase in the activity of pro-inflammatory cytokines, and GFAP increases with damage 121 
to the central nervous system (Ribotta et al., 2004). 122 
• Measures dealing with densities, mRNA or protein levels, and fold change for each of the 123 
cytokines 124 
• High transgene copy SOD1 G93A murine model (TG) B6SJL-Tg 125 
 126 
 127 
Study Exclusion Criteria 128 
• Data that did not measure cytokine counts or expressions either directly or indirectly 129 
• Measures with treatment on the mouse model 130 
• Data in which there was no evident manner to normalize the results 131 
• Purely in vitro data 132 
• Cytokine levels measured greater than 136 days (see data normalization) 133 
 134 
Data Normalization 135 
In order to account for the variation of cytokine level measurement methods between the many 136 
papers, cytokine level data were normalized by the calculation of ratios of TG to WT cytokine 137 




least one WT timepoint was present, that one WT value was used to normalize the TG value as 139 
the WT value was observed to be constant with age (Ringer et al., 2009).  Each ratio was then 140 
weighted according to the sample size found for its respective study.  When sample size values 141 
were not explicitly or clearly reported in papers (Kang et al., 2003;Weydt et al., 2004;Xie et al., 142 
2004;Kiaei et al., 2006;Kassa et al., 2009;Finkelstein et al., 2011;Audet et al., 2012;Dibaj et al., 143 
2012), a value of 1 was used for the sample size in the statistical analysis in order to allow for the 144 
data to make a conservative, yet deserved, impact on the analysis.  145 
 146 
Disease Stages 147 
The disease stages were determined by taking the mean and standard deviation of all reported 148 
time of onset (97 ± 20), and of all reported time of death (135 ± 19) in the papers included, and 149 
marking one standard deviation before and after these means as critical points for the ranges.  150 
The resultant four defined time periods are as follows: 0 to 76 days (early stage), 77 to 96 days 151 
(pre-onset stage), 97 to 116 day (post-onset stage), 117 to 135 days (end stage).  Data after the 152 
mean time of death (135 days) was excluded, since data was only available for two type I 153 
cytokines, TNF-α or GFAP.    154 
 155 
Analysis 156 
A right tailed t-test was used to test the statistical significance of the means of each cytokine 157 
level against the null hypothesis that the cytokine levels between TG and WT was unchanged for 158 
each time period or disease stage.  Shapiro-Wilk test was used to determine that the TG/WT ratio 159 
data was normally distributed.  To insure a conservative assessment, Bonferroni correction was 160 
used to lower the defined statistical significance to p < 0.002.  One-way ANOVA was used to 161 
test the significance of means for each defined time period. ANCOVA was used to test the 162 
significance of the rate of change of cytokine levels among the different cytokines, and among 163 
grouped type I and type II cytokines, for each defined time period; the significance level for this 164 
comparison was set as α = 0.05. MATLAB (The Mathworks, Inc.) was used to perform the 165 
statistical analysis. A meta-analysis with fixed effects was also conducted using metan in Stata 166 
(StataCorp, 2015). Since meta-analysis is more conservative in terms of data inclusion criteria, 167 
meta-analysis for the studies with type I cytokines was done. While the forest plots look at 168 
studies compared to each other, the meta-analysis using normalized data operates under a similar 169 
fixed effects model in which the value of each study, instead of the study itself, is weighted using 170 





Experimental in vivo data on cytokines levels in transgenic (TG) SOD1 G93A ALS mice and 176 
wild type (WT) mice was utilized from a total of 66 peer-reviewed articles, which met the study 177 
inclusion criteria. The ratio of TG to WT cytokine levels at each examined time point was 178 
calculated, resulting in total of 266 TG/WT ratios. TG/WT cytokine level ratio is plotted for each 179 
specific cytokine type over the TG mouse life span (Figure 1). Figure 2A illustrates the data 180 
included in our meta-analysis, separated by disease stage. Individual cytokines are aggregated 181 
and presented by their corresponding type, type 1 (Figure 2B) or II (Figure 2C).  Since pro-182 




ALS, type II (IL-4, IL-6, and IL-12) cytokines have been less studied in the experimental 184 
literature; consequently, there is less type II cytokine data.  185 
 186 
Differences in TG levels compared to WT levels in and across each stage  187 
In Figure 3, the means of the fold change for all cytokines within each time period is positive 188 
with the exception of the means of IL-6 and TNF-α.  At the early stage, the fold changes of IL-6 189 
(0.7214) and TNF-α (0.9369) appear to be qualitatively less than WT, but are not statistically 190 
significant. The fold changes of all the other cytokines are greater than one, indicating that the 191 
TG cytokine levels were overexpressed relative to WT cytokine levels. 192 
 193 
Among the individual type I cytokines, IL-1α, IL-1ß, and GFAP show significance in their fold 194 
increase (p < 0.0001) across all of the four stages. TNF-α shows significance in fold increase in 195 
all stages except for pre-onset, and IL-12 does not show any significance at stages where 196 
sufficient data was present to be tested.  Across aggregated type I cytokines, increase of TG 197 
levels relative to WT levels is statistically significant for each disease stage (Figure 4). 198 
 199 
Of type II cytokines, IL-6, and IL-10 show significance in increase in all stages where sufficient 200 
data were present (Figure 3, marked with *).  In contrast, IL-4 showed statistically insignificant 201 
increases in both the early and end disease stages (Figure 3). 202 
 203 
Across the four stages for type I cytokines, the GFAP level expression increased significantly 204 
across all stages (Figure 3, marked with +). TNF-α expression increased significantly across the 205 
first three stages.  IL-β levels are increased in the early, post-onset and end stages, but not for 206 
pre-onset. IL-1α, IL-12, IL-4, IL-6, and IL-10 contain missing data in crucial stages to reach 207 
conclusive results. Overall, the rate of type I cytokine levels increased significantly across the 208 
first three stages (Figure 4, marked with +).  Type II cytokines expression increased significantly 209 
across the first three stages (Figure 4, marked with +), but decreased significantly from the post-210 
onset stage to the end stage (Figure 4, marked with -).  211 
 212 
Fold change difference between type I and type II cytokines.  213 
In Figure 4, the mean fold increase of type I is not only greater than that of type II across all four 214 
stages, but the difference was also statistically significant in all four stages. The difference 215 
between the means increases from early to pre-onset stage. At the post-onset stage, the difference 216 
does not continue this increase, but, instead, decreases slightly as a result of the increase in anti-217 
inflammatory response to mediate the overexpression of the inflammatory response. Towards the 218 
end stage, the inability of the pathological system to compensate for the increase in pro-219 
inflammatory response to maintain dynamic stability is seen through the abrupt increase in the 220 
difference of the fold changes. 221 
 222 
Meta-analysis of type I cytokines 223 
Due to the type of data and the experimental heterogeneity of the assessed measures and each 224 
study’s precision, standard meta-analysis as a stand-alone method does not provide sufficient 225 
dynamical assessment (Higgins et al., 2003), in terms of examining both cytokine rate changes 226 
and fold changes.  Nonetheless, it is valuable for assessing the contributions of individual studies 227 
and providing very conservative affirmation of the quantified significance of fold change in 228 
cytokines. From the meta-analysis, there is no statistical significance in the results between each 229 




onset and end stages as shown in the results from the forest plot (see supplementary table 1).  231 
Therefore, the conservative results of the meta-analysis are supportive of the results described 232 
above using traditional statistics with Bonferroni correction.  Finally, the I2 statistics for each of 233 
these stages with the exception of pre-onset stage indicate that, as would be expected, there is 234 
considerable heterogeneity between studies.  235 
 236 
Differences in rate of change of fold changes between individual cytokines, and between type I 237 
and type II cytokines 238 
In Table 3, for each of the four time periods, both the rate of change of each cytokine compared 239 
to the average rate of change, and the rate of change of each type compared to the average rate of 240 




While end stage cytokine levels have been described in various studies on the TG model, our 245 
analysis especially sheds light on the previously underrepresented early stage and pre-onset 246 
cytokine levels (McCombe and Henderson, 2011). Overexpression of individual cytokines was 247 
expected near end stage.  However, interestingly, overexpression of individual cytokines also 248 
occurred in the early and pre-onset stages, well before the measurable appearance of physical 249 
symptoms. GFAP, a clear indicator of inflammation, is expressed twice the WT cytokine levels 250 
in the early stage, well before the onset of the disease, and the protein continues to significantly 251 
increase throughout disease progression, reaching almost 4.5 times the WT counterpart 252 
(Siemionow et al., 2009).  253 
 254 
In addition to the expected increase in pro-inflammatory type I cytokine levels in stages after 255 
onset, type I cytokine levels in TG mice also increased relative to WT mice significantly before 256 
the onset of the disease. This early deviation from the normal aggregate type I cytokine levels 257 
reveals the start of the inflammatory response well before the symptomatic stage. Overall, as a 258 
group, type II cytokines show significantly different means only in the pre-onset and post-onset 259 
stages (4, marked with *).  Unfortunately, there is a general lack of data to draw strong 260 
conclusions regarding expression of individual type II cytokines. 261 
 262 
Aggregating the individual cytokines respective to their types yields a more holistic view of the 263 
pro- and anti-inflammatory balance in ALS. Type II cytokine level rates increase appropriately 264 
across the first three stages to counteract the overexpression of type I cytokines. However, at the 265 
end stage, type II cytokines fail to maintain this appropriate response, thereby facilitating the 266 
increased effect of pro-inflammatory response on neuronal damage. This disruption in 267 
immunoregulatory balance is a remnant of the overall regulatory instability that is a contributor 268 
to ALS (Irvin et al., 2015).  269 
 270 
In response to the disruption in the balance between pro and anti-inflammatory responses via the 271 
increase in type I cytokine levels, type II cytokine levels should also increase to mediate this 272 
imbalance (Philips and Robberecht, 2011). However, type II exhibits the opposite of the 273 
appropriate response. Although both types of cytokines increase significantly over the first three 274 
stages of the disease, type I cytokine levels plateau at the end stage, but type II cytokine levels 275 




stage may have an impact on the decrease in expression of type II cytokine levels.  Interestingly, 277 
after onset, the immune system appears to balance the rates of change of the cytokines as the 278 
disease progresses, although the mean cytokine levels remain elevated. 279 
 280 
Despite the pathological state, which causes TG mice cytokine levels to be generally 281 
overexpressed, the rates at which the cytokines change across time for each stage do not indicate 282 
an aberrant cytokine. Rather, the increase or decrease of each cytokines aligns with the average 283 
change of cytokine levels in the system. This could indicate that the mechanisms which causes 284 
changes of cytokine levels over the disease progression occurs as a result of a system response 285 
against inflammation caused by the ALS pathology, such as gliosis, and not as a direct cause of 286 
the ALS pathology, itself. The lower prevalence of antecedent disease in clinical ALS population 287 
(Mitchell et al., 2015b) indicates that inflammation is likely a side effect, rather than a precursor, 288 
of ALS.    289 
 290 
The results of our study suggest that inflammation may have more of a crucial role in the earlier 291 
stages of ALS. Although gliosis through the perturbation of microglia and astrocytes by cytokine 292 
molecules act as protective barriers for normal injuries, unregulated, continued increase of pro-293 
inflammatory cytokine levels in a pathological state can cause unnecessary gliosis that cause 294 
damage and is harmful (Papadimitriou et al., 2010). As a result, immunoregulatory treatments to 295 
decrease inflammation by increasing the anti-inflammatory response may be more effective 296 
when administered earlier in the course of ALS. Such treatments administered later in the disease 297 
may have little, if any, impact since the pro-inflammatory cytokines have already reached the 298 
crucial levels. Interestingly, similar observations have been made in regards to timing the 299 
treatment of neuroinflammation in secondary spinal cord injury (Mitchell and Lee, 2008).    300 
 301 
The traditional school of thought has been to utilize type I cytokine inhibitors or type II cytokine 302 
activators to limit the high levels of inflammation. For example, a historical study that used 303 
COX-2 inhibitors as treatments showed significant decrease in inflammatory responses (McGeer 304 
and McGeer, 2002).  However, the results of the present study reveal that the ability to actually 305 
modulate the immunoregulatory response, and do so with precise timing, may be more favorable.  306 
In fact, recent studies attempting immunoregulatory modulation have shown promise.  For 307 
example, immunizations with a myelin-derived antigen have been utilized to stimulate 308 
immunoregulatory cell recruitment, ultimately attenuating disease progression in the ALS mouse 309 
model (Kunis et al., 2015).  Other strategies have included immunomodulatory effects of human 310 
mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients (Kwon et al., 311 
2014), altering the native environment of neuroprotective t-cells (Mesnard-Hoaglin et al., 2014), 312 
and the usage of IgG antibodies as biomarkers (Schwartz and Baruch, 2014).  313 
 314 
Perhaps the most exciting therapeutic hypothesis to date is to boost native autoimmunity.  315 
Autoimmune T cells are part of a cellular network which, to operate efficiently and safely, 316 
requires tight regulation by other immune cell populations, such as regulatory T cells, which are 317 
indispensable for maintenance of immunological self-tolerance and homeostasis (Schwartz and 318 
Baruch, 2014).  It has been previously suggested that dysregulation of the balance between 319 
peripheral immune suppression, on one hand, and protective autoimmunity, on the other, is an 320 
underlying mechanism in the emergence and progression of the neuroinflammatory response 321 




2014).  The dynamical instability between type I and II cytokines in SOD1 G93A ALS mice, as 323 
identified in the present study, is supportive of the immune dysregulation hypothesis.  The ability 324 
to exploit the intricate relationships and immunoregulatory pathways via cellular therapy is an 325 
exciting path for the future of ALS treatment (Rizzo et al., 2014). 326 
 327 
Finally, the testing of anti-inflammatory treatments in various time ranges, and not simple 328 
presence or absence of anti-inflammatory treatment, may achieve not only a deeper 329 
understanding of the possible mechanisms of the balance between pro- and anti-inflammatory 330 
responses, but also give rise to a more effective treatment that may further extend life 331 




It is evident that the levels of most of the individual cytokines in TG are generally higher than 336 
their corresponding WT counterpart for all four disease stages. Pro-inflammatory type I 337 
cytokines are expressed at higher levels than anti-inflammatory type II cytokines across all 338 
stages. Moreover, type I cytokine levels increase significantly across the first three stages, 339 
whereas type II cytokine levels increase significantly until the post-onset stage and then decrease 340 
at the end stage. The pronounced increase in difference between inflammatory and anti-341 
inflammatory throughout the life span of ALS mice is likely due to the inability of the 342 
pathological system to maintain stability (Mitchell and Lee, 2012). In fact, type I normalized TG 343 
levels are approximately four times greater than WT in the post-onset and end stages, whereas 344 
the type II normalized TG levels are only two times greater for the post-onset stage and almost 345 
equivalent to WT levels at end stage.  Early intervention and immunoregulatory modulation 346 
addressing the dynamic neuroinflammatory instability are two keys to future treatment success.  347 
Finally, assessment of homeostatic regulation failure in inflammation and other cellular 348 
pathways remains a promising avenue for identifying the underlying etiology of ALS (Irvin et 349 
al., 2015). 350 
 351 
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Figure Captions 690 
 691 
Figure 1. Normalized cytokine levels used to assess differences between SOD1 G93A transgenic 692 
mice (TG) and wild type (WT) mice over time or post-natal age (days). Plot of individual 693 
cytokine levels, a. IL-1ɑ, b. IL-1ß, c. IL-4, d. IL-6, e. IL-10, f. TNF-ɑ g. GFAP, and h. IL-12, 694 
used in the analysis. 695 
 696 
Figure 2. Normalized cytokine levels over time separated by the four stages utilized for 697 
statistical analysis, early (0 to 76 days), pre-onset (77 to 96 days), post-onset (97 to 116 days), 698 
and end stages (117 to 135 stages).  a. Plot of all raw data cytokine ratios (TG/WT) for type I and 699 
type II cytokines.  b. Cytokines ratios (TG/WT) for type I cytokines only.  c. Cytokine ratios 700 
(TG/WT) for type II cytokines only. 701 
 702 
Figure 3. Means of normalized cytokine levels (TG/WT) for each of the four SOD1 G93A ALS 703 
mouse disease stages: early, pre-onset, post-onset, and end. Statistically significant differences 704 
between SOD1 G93A transgenic mice (TG) and wild type (WT) levels within a disease stage are 705 
marked with asterisk (*).  Statistically significant positive or negative fold changes across 706 
consecutive disease stages are represented by plus (+) or minus (-), respectfully.  Significance 707 
was adjusted to p < 0.002 using Bonferroni correction. Error bars represent confidence interval. 708 
 709 
Figure 4. Means of normalized type I and type II for each of the four SOD1 G93A ALS mouse 710 
disease stages: early, pre-onset, post-onset, and end stage. Type I cytokines were significantly 711 
higher than type II cytokines for each of the four stages. Statistically significant differences 712 
between SOD1 G93A transgenic mice (TG) and wild type (WT) levels within a disease stage are 713 
marked with asterisk (*).  Statistically significant positive or negative fold changes across 714 
consecutive stages are represented by plus (+) or minus (-), respectfully.  Significance was 715 










Table 1. Cytokine outline. These cytokines were included in this study due to their high 723 
prevalence in the primary article pool. 724 
Cytokine Type Background Description 
IL-1α I IL-1α and IL-1ß are the interleukins most directly associated with acute 
and chronic inflammation, and they share the same receptor and 
coreceptor IL-1RI and IL-1RacP respectively (Dinarello, 2011). IL-1β I 
IL-12 I IL-12 is known as a type I T cell stimulating factor, which can stimulate 
the growth and function of T cells, including tumor necrosis factor alpha 
(TNFα) (Hsieh et al., 1993). IL-12 P70 heterodimer promotes the 
differentiation of type I helper cells which produce more type I cytokines. 
IL-12 P40 homodimer is an antagonist that is generally present when 
levels of IL-12 P70 heterodimer are in excess (Suzuki et al., 2003). 
TNF-α I TNFα is a type I cytokine released from M1 macrophages and is involved 
in triggering apoptosis (Kriegler et al., 1988). 
GFAP I Glial fibrillary acidic protein (GFAP) has been shown to be upregulated in 
autoimmune diseases where TNFα and IL-1ß were overexpressed (von 
Boyen et al., 2004), causing glial scarring as the astrocytes interact with 
neural injuries (Ribotta et al., 2004). 
IL-4 II IL-4 is the interleukin primarily responsible for the differentiation of 
helper T cells to Th2 cells that participate in the anti-inflammatory 
response (Sokol et al., 2008). 
IL-6 II IL-6 was originally defined as a pro-inflammatory cytokine secreted by T 
cells and macrophages (Ferguson-Smith et al., 1988). However, IL-6 has 
more recently been shown to have anti-inflammatory properties when 
released by muscle cells (Pedersen, 2013). 
IL-10 II IL-10 is an anti-inflammatory cytokine commonly known as human 
cytokine synthesis inhibitory factor (CSIF) (Eskdale et al., 1997). 
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Table 2. Summary of data. Information gathered on each cytokine that was suitable for use in 727 
the statistical analysis. 728 
Cytokine Total Papers Total Ratios References 
IL-4 6 7 (Hensley et al., 2002;Hensley et al., 2003;Kim et 
al., 2006;Beers et al., 2008;Chiu et al., 
2008;Audet et al., 2012) 
IL-6 8 12 (Hensley et al., 2002;Hensley et al., 2003;Weydt 
et al., 2004;Xie et al., 2004;Kim et al., 
2006;Chiu et al., 2008;Audet et al., 2012;Dibaj 
et al., 2012) 
IL-10 3 6 (Hensley et al., 2002;Hensley et al., 
2003;Finkelstein et al., 2011) 
IL-1ɑ 5 6 (Hensley et al., 2003;Kiaei et al., 2006;Kim et 
al., 2006;Kassa et al., 2009;Neymotin et al., 
2009) 
IL-1β 12 20 (Hensley et al., 2003;Kang et al., 2003;Xie et al., 
2004;Kiaei et al., 2006;Kim et al., 2006;Kassa et 
al., 2009;Neymotin et al., 2009;Fang et al., 
2010;Zhao et al., 2010;Berger et al., 2011;Audet 
et al., 2012;Valente et al., 2012) 
IL-12 6 12 (Hensley et al., 2002;Hensley et al., 
2003;Hensley et al., 2006;Kiaei et al., 2006;Kim 
et al., 2006;Dibaj et al., 2012) 
TNF-α 18 39 (Yoshihara et al., 2002;Hensley et al., 
2003;Chen et al., 2004;Weydt et al., 2004;Xie et 
al., 2004;Perrin et al., 2005;Henkel et al., 
2006;Kim et al., 2006;Zhang et al., 
2008;Cheroni et al., 2009;Neymotin et al., 
2009;Fang et al., 2010;Takeuchi et al., 
2010;Finkelstein et al., 2011;Pollari et al., 
2011;Audet et al., 2012;Valente et al., 2012) 
GFAP 46 164 (Olsen et al., 2001;Yoshihara et al., 2002;Liu 
and Martin, 2006;Ohta et al., 2006;Pardo et al., 
2006;Guan et al., 2007;Petrik et al., 2007;Yin et 
al., 2007;Beers et al., 2008;Pitzer et al., 
2008;Poesen et al., 2008;Shibata et al., 
2008;Boucherie et al., 2009;Cheroni et al., 
2009;Kassa et al., 2009;Keller et al., 




2009;Yang et al., 2009;Guo et al., 
2010;Israelsson et al., 2010;Jokic et al., 
2010;Moreno-Igoa et al., 2010;Shimazawa et al., 
2010;Steinacker et al., 2010;Suzuki et al., 
2010;Tsai et al., 2010;Berger et al., 
2011;Finkelstein et al., 2011;Genestine et al., 
2011;Guo et al., 2011;Keller et al., 2011;Yang et 
al., 2011;Zhu and Sheng, 2011;Gifondorwa et 
al., 2012;Miquel et al., 2012;Valente et al., 2012) 
Type I 
Total 
56 241 (Olsen et al., 2001;Hensley et al., 
2002;Yoshihara et al., 2002;Hensley et al., 
2003;Kang et al., 2003;Chen et al., 2004;Weydt 
et al., 2004;Xie et al., 2004;Perrin et al., 
2005;Henkel et al., 2006;Hensley et al., 
2006;Kiaei et al., 2006;Kim et al., 2006;Liu and 
Martin, 2006;Ohta et al., 2006;Pardo et al., 
2006;Guan et al., 2007;Petrik et al., 2007;Yin et 
al., 2007;Beers et al., 2008;Pitzer et al., 
2008;Poesen et al., 2008;Shibata et al., 
2008;Zhang et al., 2008;Boucherie et al., 
2009;Cheroni et al., 2009;Kassa et al., 
2009;Keller et al., 2009;Neymotin et al., 
2009;Ringer et al., 2009;Sekiya et al., 
2009;Yang et al., 2009;Fang et al., 2010;Guo et 
al., 2010;Israelsson et al., 2010;Jokic et al., 
2010;Moreno-Igoa et al., 2010;Shimazawa et al., 
2010;Steinacker et al., 2010;Suzuki et al., 
2010;Takeuchi et al., 2010;Tsai et al., 2010;Zhao 
et al., 2010;Berger et al., 2011;Finkelstein et al., 
2011;Genestine et al., 2011;Guo et al., 
2011;Keller et al., 2011;Pollari et al., 2011;Yang 
et al., 2011;Audet et al., 2012;Dibaj et al., 
2012;Gifondorwa et al., 2012;Miquel et al., 
2012;Valente et al., 2012) 
Type II 
Total 
10 25 (Hensley et al., 2002;Hensley et al., 2003;Weydt 
et al., 2004;Xie et al., 2004;Kim et al., 
2006;Beers et al., 2008;Chiu et al., 
2008;Finkelstein et al., 2011;Audet et al., 
2012;Dibaj et al., 2012) 
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Table 3. Rate of change of type I vs. type II cytokine levels at each stage. The p-value for the 732 
average slope shows the significance of slope differing from zero. None of the rates of change of 733 




Early Stage Pre-onset Stage Post-onset Stage End Stage 
slope p-value slope p-value slope p-value slope p-value 
IL-4 0.0525 -- — — 0.114 — 0.048 0.7967 
IL-6 0.086 0.678 — — 0.183 0.8791 0.079 0.7575 
IL-10 — — -0.022 — 0.114 — 0.055 0.8923 
IL-1α 0.1467 0.694     — — 0.114 — -0.293 0.4438 
IL-1ß 0.023 0.6311  -0.022 — 0.322 0.4816 -0.193 0.5885 
IL-12 0.0525 — -0.022 — 0.114 — 0.060 0.7262 
TNF-α -0.001 0.3854  -0.193 0 -0.018 0.6047 -0.197 0.4126 
GFAP 0.0079 0.4669  0.149 0 -0.031 0.4595 0.229 0.0404 
Average 0.0525 0.3918 -0.022 0.4771 0.114 0.5279 -0.034 0.759 
Type I 0.0104 0.1837 0.0658 — -0.0227 0.8224 0.242 0.356 
Type II 0.0964 0.1837 — — 0.0655 0.8224 0.05 0.356 
Average 0.0534 0.0991 — — 0.0214 0.9134 0.146 0.1619 
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